中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (5): 348-352.doi: 10.12144/zgmfskin202605348

• 临床研究 • 上一篇    下一篇

托法替布治疗获得性反应性穿通性胶原病二例并文献复习

何璐岑1,2,周桂芝1,2,张帆1,2,刘红1,2   

  1. 1山东第一医科大学附属皮肤病医院, 山东济南，250022；2山东省皮肤病性病防治研究所, 山东济南，250022
  • 出版日期:2026-05-15 发布日期:2026-05-11

Tofacitinib in the treatment of acquired reactive perforating collagenosis: two cases report and literature review

HE Lucen1,2, ZHOU Guizhi1,2, ZHANG Fan1,2, LIU Hong1,2   

  1. 1 Dermatology Hospital of Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2026-05-15 Published:2026-05-11

PDF (PC)

12

摘要： 获得性反应性穿通性胶原病(ARPC)传统治疗包括抗组胺药、局部外用维A酸、糖皮质激素和窄谱UVB光疗等，但疗效不佳。近年有JAK抑制剂治疗ARPC有效的报道，本文报道2例对托法替布反应良好的获得性反应性穿通性胶原病患者并进行文献复习。

关键词: 托法替布, 获得性反应性穿通性胶原病, JAK抑制剂

Abstract: Traditional treatments for acquired reactive perforating collagenosis include antihistamines, topical retinoids, glucocorticoids, and narrow-band UVB phototherapy, but with unsatisfactory efficacy. In recent years, there have been reports of effective treatment of ARPC with JAK inhibitors. This article reports two cases of acquired reactive perforating collagenosis that responded well to tofacitinib, along with a literature review.

Key words: tofacitinib, acquired reactive perforating collagenosis, JAK inhibitors